WHIPPANY, N.J., Oct. 12, 2017 /PRNewswire/ -- Bayer and the Society for Reproductive Investigation (SRI) today announced the launch of the SRI-Bayer Discovery and Innovation Grants Program, which will support research initiatives within SRI to advance scientific understanding and address unmet medical needs in women's health.
"SRI is excited to partner with Bayer to fulfill our mission of advancing women's health," said Sandra T. Davidge, PhD, president of SRI. "Through these grants, Bayer and SRI demonstrate a commitment to research in reproductive medicine."
The program offers grants to scientists and clinicians dedicated to research in endometriosis (including adenomyosis uteri/endometriosis internal), uterine fibroids (uterine leiomyoma) and Polycystic Ovarian Syndrome (PCOS).
"As part of Bayer's longstanding commitment to advancing women's health, supporting scientific and clinical research in key areas of unmet need is a priority," said Karl Ziegelbauer, PhD, senior vice president and head of therapeutic research groups in drug discovery at Bayer. "We're delighted to partner with SRI to support researchers working toward potential treatment options that seek to improve the lives of women suffering from gynecological conditions."
Bayer has a robust product portfolio and research pipeline in women's health, including family planning and gynecological diseases.
Bayer will provide a total of $105,000 to fund seven grants, to be awarded in March 2018 at the SRI's 65th Annual Meeting. The Requests for Applications are available through SRI until November 15, 2017. The application review and all grant award decisions are within the sole discretion of SRI. For more information, please contact the SRI Office at email@example.com or (414) 918-9888.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
Social Media Channels
- Facebook: facebook.com/BayerUnitedStates
- Twitter: twitter.com/BayerUS
- Instagram: instagram.com/BayerUS
- YouTube: youtube.com/BayerUS
The Society for Reproductive Investigation
The mission of the Society for Reproductive Investigation (SRI) is to advance reproductive and women's health care through outstanding basic, translational, and clinical science and by training and mentoring future generations of investigators. For more information, visit http://www.sri-online.org/.
© 2017 Bayer
Bayer and the Bayer Cross are registered trademarks of Bayer.
Deputy Director, Communications, Bayer
Anne N. Krolikowski, CAE
Executive Director, SRI